Comparing Taurolidine and Saline Locks for Catheter Care in Children with Cancer
Official title: Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in the Primary Prevention of Catheter-related Endoluminal Infection in Paediatric Oncology.
Run by Institut Curie · NCT05781295 · Data updated 2026-11-12
This study tests whether using a Taurolidine lock instead of a regular saline lock can help prevent infections in central catheters for kids and young adults with cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | Any age to 21 Years |
| Sex | All |
| Enrollment | 148 (estimated) |
| Sponsor | Institut Curie Academic / other |
| Locations | 5 sites (Paris and 4 other locations) |
| Status | Recruiting |
| Started | January 19, 2024 |
| Main results expected | July 23, 2028 |
| Study ends | July 23, 2028 |
| Registry record updated | February 20, 2026 |
| Trial ID | NCT05781295 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children and young adults up to 21 years old who are undergoing treatment for cancer and require a central catheter.
✕Probably not a fit
Patients with retinoblastoma, those who are allografted, or those with a life expectancy of less than 6 months may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicentric, controlled, randomized, and double-blind study aims to evaluate the effectiveness of a Taurolidine lock compared to a standard saline lock in preventing catheter-related endoluminal infections in pediatric oncology patients. Participants will be monitored based on their specific cancer treatment protocols, with either Taurolock or physiological serum used at each catheter closure. The study focuses on children and young adults up to 21 years of age who require central catheter placement for cancer treatment.
Why it matters
Potential benefit: If successful, this study could significantly reduce the incidence of infections related to central catheters in pediatric oncology patients.
How similar studies have gone: Previous studies have shown promising results with the use of Taurolidine in preventing infections in similar patient populations, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patient less than or equal to 21 years of age at inclusion. 2. Patient for whom a central catheter is planned to be inserted\*, excluding a non-tunneled femoral or cervical external catheter or a peripherally inserted central catheter (as PICC line). \*1st catheter placement or placement following a relapse (this placement must take place at least one month after previous catheter removal). 3. Patient treated for a cancer. 4. Patient with regular follow-up in the inclusion center. 5. Informed consent signed by the patient if adult or by legal representatives if minor. 6. Patient benefiting from a social security coverage. 7. Time between the date of catheter placement and the planned date for the first solution lock injection less than 6 weeks. Exclusion Criteria: 1. Patient with retinoblastoma. 2. Allografted patient. 3. Patient with a life expectancy of less than 6 months. 4. Patient refusing to participate in the protocol. 5. Patient already receiving a central venous catheter-related infection prevention lock (ILCVC). 6. Patient with known allergy to citrate or (cyclo)-Taurolidine. 7. Patient taking other drugs with a known contraindication with citrate or (cyclo)-Taurolidine. 8. Patient with an external femoral catheter. 9. Patient with a PICCLINE-type peripheral venous inserted central catheter. 10. Patient unable to submit to the medical follow-up of the trial for geographical, social or psychological reasons. 11. Patient under guardianship and curatorship.
Where it's running
-
Institut Curie
Paris, France Recruiting -
Saint Louis
Paris, France Recruiting -
Armand Trousseau
Paris, France Recruiting -
Robert Debre
Paris, France Recruiting -
Gustave Roussy
Villejuif, France Recruiting
Study contacts
- Study coordinator: Camille CORDERO, MD
- Email: camille.cordero@curie.fr
- Phone: +33172389309
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Bringing preventive cardiovascular care to Indigenous and remote communities
This project tests a mobile health unit to screen and provide culturally safe cardiovascular and metabolic care for Indigenous and remote communities in Canada.
-
Intensive versus standard care and education for cholesterol management in people with hypertension and diabetes
This project will test whether a structured, intensive dyslipidemia management and education program helps adults with hypertension and diabetes improve their blood lipid levels.
-
Bubble-like dome to contain airborne germs during endotracheal intubation
This trial tests whether placing a clear, bubble-shaped dome over a patient’s head during intubation can help reduce germ spread without making the anesthesia process harder.
-
Optimizing LDL cholesterol levels using inclisiran for patients with drug interactions
This study is testing if inclisiran can help lower LDL cholesterol in patients with multiple health issues who can't take statins due to other medications.
-
Treatment of thumb base osteoarthritis using a collagen-based medical device
This study is testing a new collagen-based treatment to see if it can help people with painful thumb arthritis feel better and improve their hand function.
-
Validation of a new MRI technique for spinal bone imaging
This study is testing a new MRI technique called BoneMRI to see if it can provide clearer images of spinal bones, helping doctors diagnose issues without using radiation from CT scans.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.